Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aculys Pharma

Explore full profile

Committed to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted…

Fujisawa, JapanFounded 2021Biotech & Life Sciences
Valuation $100–250M Last recorded · 2025
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Aculys Pharma and the history behind them.

About Aculys Pharma

Aculys is a forward-thinking startup focused on revolutionizing the treatment of sleep-related diseases. The company operates in the healthcare and pharmaceutical sector, specifically targeting nervous and mental health conditions. Aculys is dedicated to developing new drugs that offer innovative treatment options for sleep disorders, which are known to significantly impact both individual health and the broader economy. For instance, sleep-related diseases contribute to an economic loss of about 2.9% of Japan's gross national product.

Aculys serves a diverse range of clients, including patients suffering from sleep disorders, their families, healthcare professionals, and medical institutions. The company aims to improve cognitive awareness about these conditions, ensuring that more patients receive accurate diagnoses and effective treatments.

The business model of Aculys revolves around clinical drug development. This involves extensive research and testing to create new medications that can be brought to market. The company collaborates with various stakeholders, such as patients, families, medical conferences, and healthcare personnel, to enhance the understanding and management of sleep-related diseases.

Aculys generates revenue primarily through the sale of its newly developed drugs once they receive regulatory approval. Additionally, the company may engage in partnerships or licensing agreements with other pharmaceutical firms to expand the reach of its treatments.

In summary, Aculys is committed to transforming the landscape of sleep disorder treatment through innovative drug development, aiming to improve patient outcomes and reduce the economic burden of these conditions.

Source: Dealroom company data

At a glance

Status
Acquired
Founded
2021
Headquarters
Fujisawa, Japan
Employees
9
Open positions
None listed
Dealroom signal
61.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Oct 2025 $0 — Viatris ↗
SERIES BOther financing Mar 2022 $22M $86M HBM Partners · ANRI · Spiral Capital · Mitsubishi UFJ Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Aculys Pharma website traffic

Latest recorded traffic for Aculys Pharma is 2.3K monthly website visits, down 50% over the last three months. Aculys Pharma's team declined 43.8% over the past year.

Latest monthly visits2.3K 3-month web change-50% 1-year team growth-43.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • SoftBank
  • HBM Partners
  • ANRI
  • Spiral Capital
  • Mitsubishi UFJ Capital
  • Sumitomo Mitsui Trust Investment
  • Catalys Pacific
  • JIC Venture Growth Investments
  • HBM Healthcare Investments

Other known investors1 additional known investor

  • Viatris
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇯🇵 Japan63.6%
🇺🇸 United States27.3%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aculys Pharma on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aculys Pharma’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.